Triveni Bio Inc
Triveni Bio Inc. is a biotechnology company focused on developing innovative antibody treatments for inflammatory and immunological (I&I) disorders. The company is advancing its pipeline with novel therapies, including a second-generation anti-kallikrein 5/7+IL-13 bispecific antibody (TRIV-573) and its lead program TRIV-509, which is on track for an IND submission in the first quarter of 2025.
Leadership & Board
- Current Number of Employees
- 60
- Current LinkedIn Followers
- 6,961
Latest Estimated Valuation
- Estimated Valuation
- ―
- Total Amount Raised
- $180M
- Total Funding Rounds
- 2
- Latest Funding Amount
- $65M
- Latest Funding Round
- Series C
- Post-Money Valuation
- ―
Employee Trend
Triveni Bio Inc had 60 employees as of October 12, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Triveni Bio Inc had 6,961 followers as of October 12, 2026. The number of followers increased by 32 (0.46%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Jun 17, 2026 | Series C | $65.00M | ― |
| Aug 14, 2025 | Series B | $115.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Ascenta Capital | Series C |
| Janus Henderson Investors | Series C |
| Deep Track Capital | Series C |
| OrbiMed | Series B |
| Goldman Sachs Alternatives | Series B |
| Fidelity Management & Research Company | Series B |
| Deep Track Capital | Series B |
| Atlas Venture | Series B |
Similar Companies
A snapshot of private companies similar to Triveni Bio Inc, helping you discover and navigate related company profiles.
Related News and Analysis
